ALB and sarcoma: Selecting appropriate patients to undergo treatment is complex and dependant on several factors including sarcoma subtype, co-morbidities and a number of biomarkers that probably reflect disease burden, such as performance status, low albumin, anaemia etc. These challenges remain, even in an age of targeted therapies as many of these can cause cardiovascular complications [34].